Search clinical trials for: myelopreservation

Total 2 results

G1 Therapeutics, Inc.

Terminated

Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC): (PRESERVE1)

Colorectal Cancer Metastatic | Chemotherapeutic Toxicity | Myelosuppression-Adult

China, Spain, United States, Hungary, United Kingdom, Poland, Ukraine, Italy
G1 Therapeutics, Inc.
Bionical Emas

Approved for marketing

Expanded Access to Trilaciclib for Patients Receiving Chemotherapy for Small Cell Lung Cancer

Small Cell Lung Cancer | Chemotherapeutic Toxicity | Myelosuppression Adult

3

Subscribe